Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$41.68 USD

41.68
620,973

-1.01 (-2.37%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $41.66 -0.02 (-0.05%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.

Is a Surprise Coming for Immunocore (IMCR) This Earnings Season?

Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?

On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.

Investors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know

Immunocore Holdings PLC Sponsored ADR (IMCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $57.61, moving -1.69% from the previous trading session.

Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $64.51, moving +1.9% from the previous trading session.

Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $61.26 in the latest trading session, marking a -1.62% move from the prior day.

Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $63.52, moving +1.78% from the previous trading session.

Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.

Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $60.69, moving +0.03% from the previous trading session.

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $59.62, marking a -0.53% move from the previous day.

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $59.13, moving -1.58% from the previous trading session.

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?

Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?

Heska (HSKA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results

Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.

FATE To End Janssen Deal and Prioritize Pipeline Development

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.

Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA

Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.

Best Momentum Stocks to Buy for December 30th

IMCR, RGA and VCISY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2022.

New Strong Buy Stocks for December 30th

IMCR, RGA, LPLA, ACR and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2022.

Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012

The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.

Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals

Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.